Disparities in survival by insurance status in patients with Hodgkin lymphoma-Reference-Cited by-同舟云学术

Disparities in survival by insurance status in patients with Hodgkin lymphoma

Published:2015-06-08 Issue:19 Volume:121 Page:3515-3524
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Parikh Rahul R.¹²,Grossbard Michael L.³,Green B. Lee⁴,Harrison Louis B.⁵,Yahalom Joachim⁶

Affiliation:

1. Department of Radiation Oncology; Mount Sinai Beth Israel Medical Center, Mount Sinai Health System; New York New York

2. Department of Radiation Oncology; Mount Sinai Roosevelt Hospital, Mount Sinai Health System; New York New York

3. Division of Hematology-Oncology; Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center; New York New York

4. Division of Population Sciences; H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

5. Department of Radiation Oncology; H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

6. Department of Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29518/fullpdf

Reference24 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Survival disparities by Medicaid status: an analysis of 8 cancers;Koroukian;Cancer,2012

3. Gaining ground: Americans' health insurance coverage and access to care after the Affordable Care Act's first open enrollment period;Collins;Issue Brief (Commonw Fund),2014

4. Racial differences in the incidence and outcomes for patients with hematological malignancies;Flowers;Curr Probl Cancer,2007

5. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis;Halpern;Lancet Oncol,2008

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study;Current Oncology;2024-07-04

2. The Impact of Social Determinants of Health on Peripheral T Cell Lymphoma Outcomes: Treatment Center-Type Emerges as a Powerful Prognostic Indicator;2024

3. Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability;Oncotarget;2023-12-12

4. Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review;Blood Advances;2023-10-26

5. Nonbiological factors affecting outcomes in adolescents and young adults with lymphoma;Frontiers in Public Health;2023-10-18